Gerresheimer reported a consolidated net loss of €318.7 million for financial year 2025, compared with an adjusted net income of €84.3 million a year earlier. The loss was driven by non-cash depreciation, amortisation and impairments of around €521.5 million, plus exceptional charges including restructuring costs of approximately €71.8 million. Group revenue rose 16.6% to €2.3 billion on an adjusted basis, reflecting the first-time consolidation of Bormioli Pharma. Adjusted EBITDA came to €384 million, slightly below the prior year's adjusted figure of €388 million. No dividend will be paid for 2025 due to the negative consolidated net income.
Gerresheimer AGGerresheimer reported a €318.7m net loss driven by impairments and restructuring costs, and no dividend will be paid.